Status:
COMPLETED
Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
Lead Sponsor:
VA Loma Linda Health Care System
Conditions:
COPD
Inflammation
Eligibility:
All Genders
40-79 years
Phase:
PHASE1
Brief Summary
Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.
Detailed Description
Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent pr...
Eligibility Criteria
Inclusion
- Medically optimized COPD patients
- Age 40-79 years.
- serum CRP levels \>3mg/l
Exclusion
- Current smoker
- COPD exacerbation in the last 2 months.
- Active hepatic or severe renal dysfunction.
- connective tissue disease, chronic inflammatory disease, malignancy, any acute illness, leukocytosis (\>10,000 white blood cells) or thrombocytosis (\>450,000 platelets).
- Recent h/o myocardial infarction, angina in the last 6 months.
- Pregnancy.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00655993
Start Date
April 1 2008
End Date
August 1 2014
Last Update
April 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Loma Linda Health Care System
Loma Linda, California, United States, 92357